FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308378260> ?p ?o ?g. }

• W4308378260 abstract "<h3>Background</h3> We previously reported preliminary safety and efficacy results from a multi-center Phase 1 trial of CART-PSMA-TGFβRDN T-cells (TmPSMA-01; NCT04227275) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Nine pts were dosed with TmPSMA-01 across three doses ranging from 1x10⁷-3x10⁸ CAR+ cells. Evidence of clinical activity was observed, however, two pts developed severe immune-mediated toxicity and experienced Grade (Gr) 5 events. These pts had no known clinically relevant risk-factors and demonstrated disparate pre- and post-infusion clinical courses. Translational research efforts to evaluate the mechanisms of immune-mediated toxicity to TmPSMA-01 were undertaken. Results are summarized herein. <h3>Methods</h3> Pt samples collected per clinical protocol were subjected to correlative analysis platforms. Longitudinal serum and peripheral blood specimens were evaluated for soluble factors by immunoassays and TmPSMA-01 kinetics by molecular techniques, respectively. Biomarker comparisons between patients with Gr5 events and those without were made. As available, pt tissues (tumor and autopsy samples) were evaluated for TmPSMA-01 infiltration by RNA-ISH. Additionally, an <i>in vitro</i> model of immune toxicity was applied to evaluate TmPSMA-01 product potency and new CAR candidates. <h3>Results</h3> Serum cytokines from all pts showed patterns consistent with an immune-effector response but pts with Gr5 events demonstrated an elevated inflammatory signature with higher levels of IL2, IL6, GM-CSF and IL-18, among others. Peripheral expansion of TmPSMA-01 was observed and kinetics correlated with cytokine response. Autopsy evaluation from one pt with a Gr5 event showed TmPSMA-01 lymph node tumor infiltration but no presence in the sampled brain, despite clinical presentation of immune effector cell associated neurotoxicity. Finally, <i>in vitro</i> modeling of immune-toxicity demonstrated higher cytokine levels in TmPSMA-01 cell products from Gr5 pts. Using the same assay, substituting CD2 for 41BB showed a reduction in cytokine levels without impacting efficacy. <h3>Conclusions</h3> Correlative studies from pts who demonstrated severe immune-mediated toxicity following TmPSMA-01 revealed trends toward patient-intrinsic hyperinflammation. Biomarker findings suggest a contribution of IL-18 to TmPSMA-01-associated cytokine response which can be further explored for toxicity management. Moreover, we found no evidence of on-target, off-tumor involvement in the examined tissues. While a clear mechanism explaining the excessive immune-mediated response in 2 pts following TmPSMA-01 is not fully elucidated, our preclinical data demonstrate potential risk mitigation by replacing the 41BB co-stimulatory domain with CD2. Knowledge gained from these studies supported the development of a next-generation PSMA-targeting CAR, TmPSMA-02, to improve safety while maintaining anti-tumor activity and will be explored in a multi-center, Ph1/2 trial for pts with mCRPC. <h3>Ethics Approval</h3> Patients were enrolled on a WCG Institutional Review Board (IRB) approved protocol, IRB#20191909, titled “A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients with Metastatic Castration Resistant Prostate Cancer.” This clinical study was designed and implemented, and the results of the trial reported in accordance with the International Conference on Harmonization (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice with applicable local regulations and international guidances, including the 21 CFR and all ethical principles written in the Declaration of Helsinki. The clinical study protocol and the informed consent form (ICF) were both reviewed and approved by the properly chartered IRBs and Independent Ethics Committee before the study commenced. Patients enrolled in the study underwent the appropriate Screening procedures only after providing the appropriate written consent using the approved ICF for this study." @default.
• W4308378260 created "2022-11-11" @default.
• W4308378260 creator A5008321696 @default.
• W4308378260 creator A5008558372 @default.
• W4308378260 creator A5014339741 @default.
• W4308378260 creator A5035854365 @default.
• W4308378260 creator A5038758227 @default.
• W4308378260 creator A5042796405 @default.
• W4308378260 creator A5050523945 @default.
• W4308378260 creator A5052614142 @default.
• W4308378260 creator A5056459227 @default.
• W4308378260 creator A5058836432 @default.
• W4308378260 creator A5074630977 @default.
• W4308378260 creator A5077604840 @default.
• W4308378260 creator A5080489035 @default.
• W4308378260 creator A5090642552 @default.
• W4308378260 creator A5091555027 @default.
• W4308378260 date "2022-11-01" @default.
• W4308378260 modified "2023-09-30" @default.
• W4308378260 title "335 Analyses of severe immune-mediated toxicity in patients with advanced mCRPC treated with a PSMA-targeted armored CAR T-cells" @default.
• W4308378260 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0335" @default.
• W4308378260 hasPublicationYear "2022" @default.
• W4308378260 type Work @default.
• W4308378260 citedByCount "1" @default.
• W4308378260 countsByYear W43083782602023 @default.
• W4308378260 crossrefType "proceedings-article" @default.
• W4308378260 hasAuthorship W4308378260A5008321696 @default.
• W4308378260 hasAuthorship W4308378260A5008558372 @default.
• W4308378260 hasAuthorship W4308378260A5014339741 @default.
• W4308378260 hasAuthorship W4308378260A5035854365 @default.
• W4308378260 hasAuthorship W4308378260A5038758227 @default.
• W4308378260 hasAuthorship W4308378260A5042796405 @default.
• W4308378260 hasAuthorship W4308378260A5050523945 @default.
• W4308378260 hasAuthorship W4308378260A5052614142 @default.
• W4308378260 hasAuthorship W4308378260A5056459227 @default.
• W4308378260 hasAuthorship W4308378260A5058836432 @default.
• W4308378260 hasAuthorship W4308378260A5074630977 @default.
• W4308378260 hasAuthorship W4308378260A5077604840 @default.
• W4308378260 hasAuthorship W4308378260A5080489035 @default.
• W4308378260 hasAuthorship W4308378260A5090642552 @default.
• W4308378260 hasAuthorship W4308378260A5091555027 @default.
• W4308378260 hasBestOaLocation W43083782601 @default.
• W4308378260 hasConcept C121608353 @default.
• W4308378260 hasConcept C126322002 @default.
• W4308378260 hasConcept C143998085 @default.
• W4308378260 hasConcept C203014093 @default.
• W4308378260 hasConcept C2778690821 @default.
• W4308378260 hasConcept C2780192828 @default.
• W4308378260 hasConcept C2781197716 @default.
• W4308378260 hasConcept C29730261 @default.
• W4308378260 hasConcept C535046627 @default.
• W4308378260 hasConcept C55493867 @default.
• W4308378260 hasConcept C71924100 @default.
• W4308378260 hasConcept C86803240 @default.
• W4308378260 hasConcept C8891405 @default.
• W4308378260 hasConceptScore W4308378260C121608353 @default.
• W4308378260 hasConceptScore W4308378260C126322002 @default.
• W4308378260 hasConceptScore W4308378260C143998085 @default.
• W4308378260 hasConceptScore W4308378260C203014093 @default.
• W4308378260 hasConceptScore W4308378260C2778690821 @default.
• W4308378260 hasConceptScore W4308378260C2780192828 @default.
• W4308378260 hasConceptScore W4308378260C2781197716 @default.
• W4308378260 hasConceptScore W4308378260C29730261 @default.
• W4308378260 hasConceptScore W4308378260C535046627 @default.
• W4308378260 hasConceptScore W4308378260C55493867 @default.
• W4308378260 hasConceptScore W4308378260C71924100 @default.
• W4308378260 hasConceptScore W4308378260C86803240 @default.
• W4308378260 hasConceptScore W4308378260C8891405 @default.
• W4308378260 hasLocation W43083782601 @default.
• W4308378260 hasOpenAccess W4308378260 @default.
• W4308378260 hasPrimaryLocation W43083782601 @default.
• W4308378260 hasRelatedWork W2022991211 @default.
• W4308378260 hasRelatedWork W2161899978 @default.
• W4308378260 hasRelatedWork W2418638721 @default.
• W4308378260 hasRelatedWork W2783882412 @default.
• W4308378260 hasRelatedWork W2923108208 @default.
• W4308378260 hasRelatedWork W3101825804 @default.
• W4308378260 hasRelatedWork W3131562148 @default.
• W4308378260 hasRelatedWork W4243514755 @default.
• W4308378260 hasRelatedWork W4244477365 @default.
• W4308378260 hasRelatedWork W4294130762 @default.
• W4308378260 isParatext "false" @default.
• W4308378260 isRetracted "false" @default.
• W4308378260 workType "article" @default.